vs
Side-by-side financial comparison of AMICUS THERAPEUTICS, INC. (FOLD) and TG THERAPEUTICS, INC. (TGTX). Click either name above to swap in a different company.
TG THERAPEUTICS, INC. is the larger business by last-quarter revenue ($192.6M vs $185.2M, roughly 1.0× AMICUS THERAPEUTICS, INC.). TG THERAPEUTICS, INC. runs the higher net margin — 12.0% vs 0.9%, a 11.1% gap on every dollar of revenue. On growth, TG THERAPEUTICS, INC. posted the faster year-over-year revenue change (78.0% vs 23.7%). TG THERAPEUTICS, INC. produced more free cash flow last quarter ($19.6M vs $16.0M). Over the past eight quarters, TG THERAPEUTICS, INC.'s revenue compounded faster (74.2% CAGR vs 29.5%).
Amicus Therapeutics, Inc. is a public American biopharmaceutical company based in Philadelphia, Pennsylvania. The company went public in 2007 under the Nasdaq trading symbol FOLD. This followed a 2006 planned offering and subsequent withdrawal, which would have established the trading symbol as AMTX Prior to their IPO, Amicus was funded by a variety of venture capital firms including Radius Ventures, Canaan Partners and New Enterprise Associates.
TG Therapeutics is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for patients with B-cell malignancies, autoimmune diseases and neurodegenerative disorders. Its core operating markets are North America and Europe, with key product segments including targeted monoclonal antibodies and oral small molecule treatments.
FOLD vs TGTX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $185.2M | $192.6M |
| Net Profit | $1.7M | $23.0M |
| Gross Margin | 85.7% | 80.2% |
| Operating Margin | 8.6% | 26.2% |
| Net Margin | 0.9% | 12.0% |
| Revenue YoY | 23.7% | 78.0% |
| Net Profit YoY | -88.5% | -1.3% |
| EPS (diluted) | $0.00 | $0.14 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $185.2M | $192.6M | ||
| Q3 25 | $169.1M | $161.7M | ||
| Q2 25 | $154.7M | $141.1M | ||
| Q1 25 | $125.2M | $120.9M | ||
| Q4 24 | $149.7M | $108.2M | ||
| Q3 24 | $141.5M | $83.9M | ||
| Q2 24 | $126.7M | $73.5M | ||
| Q1 24 | $110.4M | $63.5M |
| Q4 25 | $1.7M | $23.0M | ||
| Q3 25 | $17.3M | $390.9M | ||
| Q2 25 | $-24.4M | $28.2M | ||
| Q1 25 | $-21.7M | $5.1M | ||
| Q4 24 | $14.7M | $23.3M | ||
| Q3 24 | $-6.7M | $3.9M | ||
| Q2 24 | $-15.7M | $6.9M | ||
| Q1 24 | $-48.4M | $-10.7M |
| Q4 25 | 85.7% | 80.2% | ||
| Q3 25 | 88.5% | 82.6% | ||
| Q2 25 | 90.2% | 86.6% | ||
| Q1 25 | 90.7% | 87.1% | ||
| Q4 24 | 90.1% | 85.8% | ||
| Q3 24 | 90.6% | 88.9% | ||
| Q2 24 | 91.1% | 88.7% | ||
| Q1 24 | 87.7% | 91.4% |
| Q4 25 | 8.6% | 26.2% | ||
| Q3 25 | 20.3% | 18.2% | ||
| Q2 25 | -6.1% | 24.7% | ||
| Q1 25 | -6.3% | 7.1% | ||
| Q4 24 | 10.7% | 27.7% | ||
| Q3 24 | 15.3% | 14.8% | ||
| Q2 24 | 11.8% | 12.0% | ||
| Q1 24 | -25.1% | -14.6% |
| Q4 25 | 0.9% | 12.0% | ||
| Q3 25 | 10.2% | 241.7% | ||
| Q2 25 | -15.8% | 20.0% | ||
| Q1 25 | -17.3% | 4.2% | ||
| Q4 24 | 9.8% | 21.6% | ||
| Q3 24 | -4.8% | 4.6% | ||
| Q2 24 | -12.4% | 9.4% | ||
| Q1 24 | -43.9% | -16.9% |
| Q4 25 | $0.00 | $0.14 | ||
| Q3 25 | $0.06 | $2.43 | ||
| Q2 25 | $-0.08 | $0.17 | ||
| Q1 25 | $-0.07 | $0.03 | ||
| Q4 24 | $0.05 | $0.16 | ||
| Q3 24 | $-0.02 | $0.02 | ||
| Q2 24 | $-0.05 | $0.04 | ||
| Q1 24 | $-0.16 | $-0.07 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $293.5M | $142.0M |
| Total DebtLower is stronger | $392.7M | — |
| Stockholders' EquityBook value | $274.2M | $648.0M |
| Total Assets | $949.9M | $1.1B |
| Debt / EquityLower = less leverage | 1.43× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $293.5M | $142.0M | ||
| Q3 25 | $263.8M | $131.6M | ||
| Q2 25 | $231.0M | $251.9M | ||
| Q1 25 | $250.6M | $276.2M | ||
| Q4 24 | $249.9M | $311.0M | ||
| Q3 24 | $249.8M | $341.0M | ||
| Q2 24 | $260.1M | $217.3M | ||
| Q1 24 | $239.6M | $209.8M |
| Q4 25 | $392.7M | — | ||
| Q3 25 | $392.0M | — | ||
| Q2 25 | $391.3M | — | ||
| Q1 25 | $390.7M | — | ||
| Q4 24 | $390.1M | — | ||
| Q3 24 | $389.5M | — | ||
| Q2 24 | $388.9M | — | ||
| Q1 24 | $388.4M | — |
| Q4 25 | $274.2M | $648.0M | ||
| Q3 25 | $230.4M | $607.2M | ||
| Q2 25 | $204.3M | $276.4M | ||
| Q1 25 | $193.6M | $237.3M | ||
| Q4 24 | $194.0M | $222.4M | ||
| Q3 24 | $178.8M | $192.2M | ||
| Q2 24 | $132.5M | $177.6M | ||
| Q1 24 | $130.7M | $160.1M |
| Q4 25 | $949.9M | $1.1B | ||
| Q3 25 | $868.8M | $1.0B | ||
| Q2 25 | $815.3M | $702.6M | ||
| Q1 25 | $789.8M | $656.7M | ||
| Q4 24 | $785.0M | $577.7M | ||
| Q3 24 | $786.6M | $586.0M | ||
| Q2 24 | $749.5M | $401.2M | ||
| Q1 24 | $721.8M | $373.3M |
| Q4 25 | 1.43× | — | ||
| Q3 25 | 1.70× | — | ||
| Q2 25 | 1.92× | — | ||
| Q1 25 | 2.02× | — | ||
| Q4 24 | 2.01× | — | ||
| Q3 24 | 2.18× | — | ||
| Q2 24 | 2.93× | — | ||
| Q1 24 | 2.97× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $16.3M | $19.7M |
| Free Cash FlowOCF − Capex | $16.0M | $19.6M |
| FCF MarginFCF / Revenue | 8.6% | 10.2% |
| Capex IntensityCapex / Revenue | 0.2% | 0.0% |
| Cash ConversionOCF / Net Profit | 9.62× | 0.85× |
| TTM Free Cash FlowTrailing 4 quarters | $29.8M | $-25.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $16.3M | $19.7M | ||
| Q3 25 | $35.7M | $-23.2M | ||
| Q2 25 | $-26.5M | $7.4M | ||
| Q1 25 | $7.8M | $-28.7M | ||
| Q4 24 | $-3.9M | $-25.6M | ||
| Q3 24 | $-23.0M | $-12.2M | ||
| Q2 24 | $22.7M | $5.5M | ||
| Q1 24 | $-29.7M | $-8.2M |
| Q4 25 | $16.0M | $19.6M | ||
| Q3 25 | $35.3M | $-23.2M | ||
| Q2 25 | $-28.9M | $7.4M | ||
| Q1 25 | $7.5M | $-28.7M | ||
| Q4 24 | $-4.2M | $-25.7M | ||
| Q3 24 | $-23.3M | $-12.2M | ||
| Q2 24 | $21.6M | — | ||
| Q1 24 | $-31.5M | — |
| Q4 25 | 8.6% | 10.2% | ||
| Q3 25 | 20.9% | -14.4% | ||
| Q2 25 | -18.7% | 5.2% | ||
| Q1 25 | 6.0% | -23.8% | ||
| Q4 24 | -2.8% | -23.7% | ||
| Q3 24 | -16.5% | -14.6% | ||
| Q2 24 | 17.0% | — | ||
| Q1 24 | -28.5% | — |
| Q4 25 | 0.2% | 0.0% | ||
| Q3 25 | 0.2% | 0.0% | ||
| Q2 25 | 1.6% | 0.0% | ||
| Q1 25 | 0.2% | 0.0% | ||
| Q4 24 | 0.2% | 0.0% | ||
| Q3 24 | 0.3% | 0.0% | ||
| Q2 24 | 0.9% | 0.0% | ||
| Q1 24 | 1.6% | 0.0% |
| Q4 25 | 9.62× | 0.85× | ||
| Q3 25 | 2.06× | -0.06× | ||
| Q2 25 | — | 0.26× | ||
| Q1 25 | — | -5.67× | ||
| Q4 24 | -0.27× | -1.10× | ||
| Q3 24 | — | -3.15× | ||
| Q2 24 | — | 0.80× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FOLD
| Other | $105.8M | 57% |
| Galafold | $64.8M | 35% |
| Pombiliti Opfolda | $14.6M | 8% |
TGTX
| Products | $189.1M | 98% |
| License | $3.5M | 2% |
